help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horwitz, K. B.
Right arrow Articles by McGuire, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horwitz, K. B.
Right arrow Articles by McGuire, W. L.

Endocrinology, Vol 103, 1742-1751, Copyright © 1978 by Endocrine Society


ARTICLES

Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen

KB Horwitz, Y Koseki and WL McGuire

Estrogen antagonists are widely used in the treatment of breast cancer, and studies of their mechanism of action may provide clues to an understanding of tumor growth regulation and mechanisms of normal estrogen action. We have used human breast cancer cells in long term culture as an in vitro model to study the roles of estradiol and the antiestrogens, tamoxifen and nafoxidine, on cell growth and progesterone receptor (PgR) induction. Tamoxifen is found to have dual dose-dependent estrogenic/antiestrogenic properties. With 1 micrometer tamoxifen, cell growth and PgR induction are suppressed. These effects are reversed by estradiol. At lower doses (less than 0.1 micrometer), however, tamoxifen is a potent estrogen and rapidly induces (24--48 h) PgR, which increases 4- to 10-fold after 4--6 days and falls if tamoxifen is removed. Induction of PgR by estradiol is weaker but follows a similar time course. Tamoxifen-induced PgR is similar to that induced by estradiol; it sediments at 8S on sucrose density gradients, is a tight binder (R5020 Kd, 1.7 micrometer at 4 C and 0.87 nM at 15 C), and can be translocated to the nucleus by R5020. The dual properties of tamoxifen are not due to metabolic formation of an active antiestrogen from a prohormone precursor. In contrast, the action of the antiestrogen nafoxidine is not biphasic in MCF-7 cells; it does not induce PgR over a wide dose range and at high doses, the compound inhibits cell growth.


This article has been cited by other articles:


Home page
Cancer Res.Home page
J. C. Harrell, W. W. Dye, D. M.E. Harvell, M. Pinto, P. Jedlicka, C. A. Sartorius, and K. B. Horwitz
Estrogen Insensitivity in a Model of Estrogen Receptor Positive Breast Cancer Lymph Node Metastasis
Cancer Res., November 1, 2007; 67(21): 10582 - 10591.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
L. C Murphy and P. H Watson
Is oestrogen receptor- {beta} a predictor of endocrine therapy responsiveness in human breast cancer?
Endocr. Relat. Cancer, June 1, 2006; 13(2): 327 - 334.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. Lin, J. Kokontis, F. Tang, B. Godfrey, S. Liao, A. Lin, Y. Chen, and J. Xiang
Androgen and its receptor promote bax-mediated apoptosis.
Mol. Cell. Biol., March 1, 2006; 26(5): 1908 - 1916.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. Arpino, H. Weiss, A. V. Lee, R. Schiff, S. De Placido, C. K. Osborne, and R. M. Elledge
Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance
J Natl Cancer Inst, September 7, 2005; 97(17): 1254 - 1261.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
B. M. Jacobsen, S. A. Schittone, J. K. Richer, and K. B. Horwitz
Progesterone-Independent Effects of Human Progesterone Receptors (PRs) in Estrogen Receptor-Positive Breast Cancer: PR Isoform-Specific Gene Regulation and Tumor Biology
Mol. Endocrinol., March 1, 2005; 19(3): 574 - 587.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
R. C. Hovey, M. Asai-Sato, A. Warri, B. Terry-Koroma, N. Colyn, E. Ginsburg, and B. K. Vonderhaar
Effects of Neonatal Exposure to Diethylstilbestrol, Tamoxifen, and Toremifene on the BALB/c Mouse Mammary Gland
Biol Reprod, February 1, 2005; 72(2): 423 - 435.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. P. Alao, E. W-F. Lam, S. Ali, L. Buluwela, W. Bordogna, P. Lockey, R. Varshochi, A. V. Stavropoulou, R. C. Coombes, and D. M. Vigushin
Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor {alpha}-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines
Clin. Cancer Res., December 1, 2004; 10(23): 8094 - 8104.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Lu, A. Pierron, and K. Ravid
An Adenosine Analogue, IB-MECA, Down-Regulates Estrogen Receptor {alpha} and Suppresses Human Breast Cancer Cell Proliferation
Cancer Res., October 1, 2003; 63(19): 6413 - 6423.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Dowsett, N. J. Bundred, A. Decensi, R. C. Sainsbury, Y. Lu, M. J. Hills, F. J. Cohen, P. Veronesi, M. E. R. O'Brien, T. Scott, et al.
Effect of Raloxifene on Breast Cancer Cell Ki67 and Apoptosis: A Double-Blind, Placebo-controlled, Randomized Clinical Trial in Postmenopausal Patients
Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 961 - 966.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. F. Robertson, R. I. Nicholson, N. J. Bundred, E. Anderson, Z. Rayter, M. Dowsett, J. N. Fox, J. M. W. Gee, A. Webster, A. E. Wakeling, et al.
Comparison of the Short-Term Biological Effects of 7{alpha}-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17{beta}-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer
Cancer Res., September 1, 2001; 61(18): 6739 - 6746.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Dowsett, J. M. Dixon, K. Horgan, J. Salter, M. Hills, and E. Harvey
Antiproliferative Effects of Idoxifene in a Placebo-controlled Trial in Primary Human Breast Cancer
Clin. Cancer Res., June 1, 2000; 6(6): 2260 - 2267.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
K.-M. Lau, S. C. Mok, and S.-M. Ho
Expression of human estrogen receptor-alpha and -beta , progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells
PNAS, May 11, 1999; 96(10): 5722 - 5727.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T.-Y. Chun, D. Gregg, D. K. Sarkar, and J. Gorski
Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth
PNAS, March 3, 1998; 95(5): 2325 - 2330.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
N. Guthrie, A. Gapor, A. F. Chambers, and K. K. Carroll
Inhibition of Proliferation of Estrogen Receptor-Negative MDA-MB-435 and -Positive MCF-7 Human Breast Cancer Cells by Palm Oil Tocotrienols and Tamoxifen, Alone and in Combination
J. Nutr., March 1, 1997; 127(3): 544 - 544.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
U. Gundimeda, Z.-H. Chen, and R. Gopalakrishna
Tamoxifen Modulates Protein Kinase C via Oxidative Stress in Estrogen Receptor-negative Breast Cancer Cells
J. Biol. Chem., June 7, 1996; 271(23): 13504 - 13514.
[Abstract] [Full Text] [PDF]


Home page
Palliat MedHome page
J. H Kearsley
Some basic guidelines in the use of chemotherapy for patients with incurable malignancy
Palliative Medicine, January 1, 1994; 8(1): 11 - 17.
[Abstract] [PDF]


Home page
ScienceHome page
S. Shafie
Estrogen and the growth of breast cancer: new evidence suggests indirect action
Science, August 8, 1980; 209(4457): 701 - 702.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1978 by The Endocrine Society